BioCentury on BioBusiness,
Politics and Policy
Obama proposes reneging on healthcare deal; would cut biologics exclusivity
What one hand giveth . . .
Monday, February 21, 2011
In case there was any doubt, the White House made clear last
week its deal with the Pharmaceutical
Research and Manufacturers of America to support healthcare reform had
a December 2010 expiration date.
PhRMA learned how perishable its deal was on Valentine's day,
when President Obama's fiscal 2012 budget proposal was released. It asked
Congress to abrogate a key part of the PhRMA deal - and the most important
element for the Biotechnology
Industry Organization - by slashing the exclusivity for pioneer
biologics to seven years from the 12 years established in the Patient Protection
and Affordable Care Act.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]